

Acute respiratory distress syndrome (ARDS) – Pipeline Insight, 2020

<https://marketpublishers.com/r/A4690BFFF1DEEN.html>

Date: September 2020

Pages: 110

Price: US\$ 2,500.00 (Single User License)

ID: A4690BFFF1DEEN

Abstracts

This report can be delivered to the clients within 72 - 96 Hours

DelveInsight's, "Acute respiratory distress syndrome (ARDS) – Pipeline Insight, 2020," report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Acute respiratory distress syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Acute respiratory distress syndrome Understanding

Acute respiratory distress syndrome (ARDS): Overview

Acute respiratory distress syndrome (ARDS) is a life-threatening condition of seriously ill patients, characterized by poor oxygenation, pulmonary infiltrates, and acuity of onset. On a microscopic level, the disorder is associated with capillary endothelial injury and diffuse alveolar damage. Acute respiratory distress syndrome is defined as an acute disorder that starts within 7 days of the inciting event and is characterized by bilateral lung infiltrates and severe progressive hypoxemia in the absence of any evidence of cardiogenic pulmonary edema. ARDS is defined by the patient's oxygen in arterial blood (PaO₂) to the fraction of the oxygen in the inspired air (FiO₂). These patients have a

PaO₂/FiO₂ ratio of less than 300.

Symptoms

Acute respiratory distress syndrome usually develops within 24 to 48 hours of the original injury or disease but may take as long as 4 or 5 days to occur. The person first has shortness of breath, usually with rapid, shallow breathing.

Common symptoms and signs of ARDS include:

- labored and rapid breathing
- muscle fatigue and general weakness
- low blood pressure
- discolored skin or nails
- a dry, hacking cough
- a fever
- headaches
- a fast pulse rate
- mental confusion

Diagnosis

A doctor can diagnose ARDS in several different ways. There's no one definitive test for diagnosing this condition. The doctor may take a blood pressure reading, perform a physical exam, and recommend any of the following tests:

- a blood test
- a chest X-ray

a CT scan

throat and nose swabs

an electrocardiogram

an echocardiogram

an airway examination

Treatment

No drug has proved beneficial in the prevention or management of acute respiratory distress syndrome. The chief treatment strategy is supportive care and focuses on 1) reducing shunt fraction, 2) increasing oxygen delivery, 3) decreasing oxygen consumption, and 4) avoiding further injury. Early administration of corticosteroids to septic patients does not prevent the development of acute respiratory distress syndrome.

Acute respiratory distress syndrome Emerging Drugs Chapters

This segment of the Acute respiratory distress syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acute respiratory distress syndrome Emerging Drugs

HCR040: HistoCell, S.L.

HCR040 is an investigational medicinal product whose active substance is HC016, allogeneic adipose-derived adult mesenchymal stem cells expanded and pulsed with H₂O₂. The main purpose of this study is to evaluate the safety and tolerability of a single administration of HCR040 using: a) two sequential escalating doses administered 96 hours post-injury to participants with moderate to severe acute respiratory distress syndrome (ARDS); and b) the determined maximum tolerated dose administered 96

hours post-injury to participants with moderate to severe ARDS. The study also includes initial exploration of efficacy.

HLCM051(MultiStem): Healios

Healios is conducting an open-label, standard therapy as a controlled, multicenter phase 2 study to evaluate the efficacy and safety of HLCM051 (MultiStem) in patients with Acute Respiratory Distress Syndrome (ARDS) caused by pneumonitis. The primary object of this clinical study is to investigate the efficacy of HLCM051 in patients with ARDS caused by pneumonitis.

Further product details are provided in the report.....

Acute respiratory distress syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Acute respiratory distress syndrome drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Acute respiratory distress syndrome

There are approx. 50+ key companies which are developing the therapies for Acute respiratory distress syndrome. The companies which have their Acute respiratory distress syndrome drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Sage Therapeutics, Healios, Chiesi Farmaceutici etc.

Phases

DelveInsight's report covers around 50+ products under different phases of clinical development like

Mid-stage products (Phase II and Phase I/II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Acute respiratory distress syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Subcutaneous

Intramuscular

Intravenous

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal antibodies

Stem cell therapies

Immunoproteins

Peptides

Proteins

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acute respiratory distress syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I,

preclinical and discovery stage. It also analyses Acute respiratory distress syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute respiratory distress syndrome drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Acute respiratory distress syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Acute respiratory distress syndrome.

Several trials are currently ongoing evaluating experimental therapies for Acute respiratory distress syndrome, including human mesenchymal stem cells and extracorporeal membrane oxygenation (ECMO).

Acute respiratory distress syndrome Report Insights

Acute respiratory distress syndrome Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Acute respiratory distress syndrome Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Acute respiratory distress syndrome drugs?

How many Acute respiratory distress syndrome drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute respiratory distress syndrome?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acute respiratory distress syndrome therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Acute respiratory distress syndrome and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Athersys, Inc

Histocell

BioXcellerator

Altor BioScience

Cartesian Therapeutics

Meridigen Biotech Co., Ltd.

Sage Therapeutics

Healios K.K.

Chiesi Farmaceutici

Bayer

Altor BioScience

Faron Pharmaceuticals Ltd

AVM Biotechnology LLC

Amyndas Pharmaceuticals S.A.

Kinevant Sciences GmbH

Eli Lilly and Company

Suntory Pharmaceutical

Key Products

MultiStem

HCR040

Wharton's jelly derived Mesenchymal stem cells.

TNX-832

Descartes 30

UMC119-06

HLCM051

CUROSURF

BAY1097761

ALT-836

Interferon Beta

AMY-101

Contents

Introduction

Executive Summary

Acute respiratory distress syndrome: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Acute respiratory distress syndrome – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Acute respiratory distress syndrome companies' collaborations, Licensing, Acquisition
-Deal Value Trends

Acute respiratory distress syndrome Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Ravulizumab: Alexion Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

HLCM051: Healios

Product Description

Research and Development

Product Development Activities

Poractant alfa: Chiesi Farmaceutici

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

Research programme: cell-based lung disorder therapeutics: Northern Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Acute respiratory distress syndrome Key Companies

Acute respiratory distress syndrome Key Products

Acute respiratory distress syndrome- Unmet Needs

Acute respiratory distress syndrome- Market Drivers and Barriers

Acute respiratory distress syndrome- Future Perspectives and Conclusion

Acute respiratory distress syndrome Analyst Views

Acute respiratory distress syndrome Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Acute respiratory distress syndrome

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Acute respiratory distress syndrome

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Acute respiratory distress syndrome (ARDS) – Pipeline Insight, 2020

Product link: <https://marketpublishers.com/r/A4690BFFF1DEEN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A4690BFFF1DEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970